Funding news
ChAbS (Chinese Antibody Society) logo

ChAbS Secures $101.0M Series B Funding

Recently funded · $101.0M Series bHospitals and Health CareUSView source

Get the full ChAbS (Chinese Antibody Society) company profile

Access contacts, investors, buying signals & more

Open in Dashboard

The Chinese Antibody Society (ChAbS), a global professional organization dedicated to advancing antibody-based therapeutics, has closed a Series B funding round, bringing in $101.0M. The capital infusion will support its mission to foster collaboration across the discovery, development, manufacturing, and marketing of therapeutic antibodies.

As an independent non-profit, non-government society, ChAbS connects industry, academics, healthcare providers, and investors. It serves as a nurturing platform for interaction and networking among its worldwide members, and also publishes its official journal, Antibody Therapeutics, in collaboration with Oxford University Press.

Other United States companies recently funded

View all

Biggest recent Biotechnology rounds

Largest funding rounds in Biotechnology on Signalbase right now.

#CompanyAmount
1
Shockwave Medical logo

Shockwave Medical

United States

$13.1B
2
NeuroEM Therapeutics logo

NeuroEM Therapeutics

United States

$7.2B
3
Illumina logo

Illumina

United States

$7.1B
4
GRAIL logo

GRAIL

United States

$7.1B
5
RemeGen Biosciences logo

RemeGen Biosciences

United States

$5.6B

Other recent Series b rounds

Companies that recently closed a Series b round.

#CompanyAmount
1
EqualAI logo

EqualAI

United States

$30.0M
2
PhoenixAI logo

PhoenixAI

United States

$80.0M
3
Coram AI logo

Coram AI

United States

$35.0M
4
City Therapeutics logo

City Therapeutics

$99.5M
5
Mygate logo

Mygate

India

$23.6M